Modality
mRNA
MOA
TYK2i
Target
IL-13
Pathway
DDR
GBMETPompe
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
~Jul 2018
→ ~Oct 2019
Phase 2
~Jan 2020
→ ~Apr 2021
Phase 3
Jul 2021
→ Aug 2028
Phase 3Current
NCT04511223
1,989 pts·GBM
2022-09→2028-06·Not yet recruiting
NCT07094889
2,356 pts·ET
2025-05→2028-02·Completed
NCT07194718
2,971 pts·GBM
2025-12→2028-08·Active
+1 more trial
8,500 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-11-125mo agoPh3 Readout· ET
2028-02-141.9y awayPh3 Readout· ET
2028-06-032.2y awayPh3 Readout· GBM
2028-08-062.4y awayPh3 Readout· GBM
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Complet…
P3
Not yet…
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2025-11-12 · 5mo ago
ET
Ph3 Readout
2028-02-14 · 1.9y away
ET
Ph3 Readout
2028-06-03 · 2.2y away
GBM
Ph3 Readout
2028-08-06 · 2.4y away
GBM
ActiveCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04511223 | Phase 3 | GBM | Not yet recr... | 1989 | CR |
| NCT07094889 | Phase 3 | ET | Completed | 2356 | Safety |
| NCT07194718 | Phase 3 | GBM | Active | 2971 | HAM-D |
| NCT07163503 | Phase 3 | ET | Completed | 1184 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Sotorapivir | Moderna | Approved | FLT3 |